/PRNewswire/ Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to modulate gene expression, today announced that.
Key Takeaways: • Tom Group returned to the red in the first half of this year, after posting its first annual profit last year since 2018 • The company earns most of its revenue from a Taiwan publishing unit, and also invests in tech companies By Edith Terry